Stereotaxis, Inc. (STXS)
Market Cap | 249.07M |
Revenue (ttm) | 31.81M |
Net Income (ttm) | -24.64M |
Shares Out | 92.25M |
EPS (ttm) | -0.29 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 699,915 |
Open | 2.680 |
Previous Close | 2.660 |
Day's Range | 2.614 - 2.710 |
52-Week Range | 1.540 - 2.716 |
Beta | 1.51 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 7, 2025 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminat... [Read more]
Financial Performance
In 2024, Stereotaxis's revenue was $26.92 million, an increase of 0.55% compared to the previous year's $26.77 million. Losses were -$25.35 million, 14.9% more than in 2023.
Financial StatementsNews

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference...

Stereotaxis Reports 2025 Second Quarter Financial Results
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has re...

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock
ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has e...

Stereotaxis: Recurring Revenue Inflection
I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin dispo...

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publicatio...

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Partic...

Stereotaxis Reports 2025 First Quarter Financial Results
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host ...

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA h...

Stereotaxis to Present at 37th Annual Roth Conference
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...

Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep...

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulator...

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulator...

Stereotaxis Reports 2024 Full Year Financial Results
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

Stock Market Sleeps On Stereotaxis MAGiC CE Mark
Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. T...

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

Stereotaxis Announces First GenesisX Robotic System Order
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has receive...

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv...

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Na...